**ISICR OFFICERS**

President  
Kathryn Zoon  

President-Elect  
Keiko Ozato  

Secretary  
Sidney Pestka  

Treasurer  
Sam Baron

---

**October 2000**  
Volume 7, No.3

---

**2000 Meeting**

November 5-9  
Amsterdam  
http://www.fbu.uu.nl/meeting2000/index.html

---

**Future ISICR Meetings**

2001 Cleveland, OH  
2002 Torino, Italy  
Joint ISICR/ICS  
2003 Melbourne

---

**ISICR WWW SITE**  
www.ISICR.org

---

**ISICR BUSINESS OFFICE**  
ISICR@faseb.org  
TEL: 301-571-8319  
FAX: 301-530-7049

---

**ISICR NEWSLETTER EDITORS**  
Howard Young  
youngh@mail.ncifcrf.gov  
Fax: 301-846-1673

Pat Fitzgerald-Bocarsly  
Bocarsly@umdnj.edu  
Fax: 973-972-7293

Hannah Nguyen  
nguyenh@cesmtp.ccf.org  
Fax: 216-445-9769

---

**2000 ISICR Awards**

The 2000 Milstein Award  

**John KIRKWOOD**  
University of Pittsburgh

**Moshe TALPAZ**  
University of Texas

---

**Honorary Membership**  

**Peter LENGYEL**  
Yale University

---

**Young Investigator Awards**  

**Siddharth BALACHANDRAN**  
Miami, FL, USA  
Jesus GIL  
Madrid, Spain

**Matt PAULSON**  
New York, NY, USA  
**Silvio PEREA RODRIGUEZ**  
La Havane, Cuba  
Dominique REBOUILLAT  
Cleveland, OH, USA

---

**The Christina Fleischmann Memorial Award**  

Reiko HORAI  
Tokyo, Japan

---

**Third Joint Meeting of the ISICR /ICS**  
Nov. 5-9, 2000  
RAI Amsterdam  
The Netherlands  
http://www.fbu.uu.nl/meeting2000/

---

**IMPORTANT DATE**  
October 31, 2000  
Deadline for advance meeting registration  
After this date registration must be made at the meeting.

---

**Registration Fees**

<table>
<thead>
<tr>
<th></th>
<th>Early*</th>
<th>Advance</th>
<th>At the meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members</td>
<td>400 Euro</td>
<td>500 Euro</td>
<td>600 Euro</td>
</tr>
<tr>
<td>Non Members</td>
<td>500 Euro</td>
<td>600 Euro</td>
<td>700 Euro</td>
</tr>
<tr>
<td>Students***</td>
<td>300 Euro</td>
<td>350 Euro</td>
<td>400 Euro</td>
</tr>
<tr>
<td>Guests/spouse</td>
<td>250 Euro</td>
<td>275 Euro</td>
<td>300 Euro</td>
</tr>
</tbody>
</table>

* Not later than August 31, 2000  
** After September 1 and before November 1, 2000  
*** Students must provide a document of university registration

---

The above fees include V.A.T. of 17.5 %.
**Preliminary Program**

**Sunday November 5**

13.00-19.00 Committee Meetings  
16.00-19.00 Registration  
19.00-20.00 Opening Ceremony  
H. Schellekens  
CHAIRPERSON LOCAL ORGANISING COMMITTEE  
20.00-21.30 Reception

**Monday November 6**

8.30-10.00  
Review Lectures:  
S. Durum  
CHAIRPERSON

8.30  
A. Rao  
MODULATION OF CHROMATIN STRUCTURE REGULATES CYTOKINE GENE EXPRESSION DURING T CELL DIFFERENTIATION

9.15  
C. Dinarello  
IL-18

10.00-10.30  
Coffee Break

10.30-12.15  
Parallel workshops

10.30-12.15  
Cytokines and T cell differentiatation:  
A. Rao  
CHAIRPERSON  
T. Kishimoto  
CHAIRPERSON

10:30  
P. Vieira  
EXPOSURE OF MATURING DC TO IFN-γ RESULTS IN THEIR STABLE TYPE-1-POLARIZED EFFECTOR PHENOTYPE

10:45  
E.C. De Jong  
PATHOGENS EVOKE PROTECTIVE TH1/TH2 RESPONSES VIA THE INDUCTION OF TYPE 1 AND TYPE 2 EFFECTOR DC

11.00  
G. Bellone  
PANCREATIC CELL CARCINOMA-DERIVED INTERLEUKIN-10 AND VASCULAR ENDOTHELIAL FACTOR DIFFERENTIALLY AFFECT DENDRITIC CELL DEVELOPMENT

11.15  
H. Smits  
TRANSCRIPTION FACTORS T-BET AND GATA-3 ARE RECIPROCALLY INVOLVED IN HUMAN Th1 AND Th2 CELL POLARISATION

11:30  
E. Dondi  
MODULATION OF IFN-α/β SENSITIVITY UPON IL-12 RECEPTOR UP-REGULATION IN HUMAN T CELLS

11:45  
K.U. Uno  
DIFFERENTIAL RESPONSE OF CD4+ AND CD8+ T CELLS TO IL-12 OR IL-18 DEPENDING ON THE IMMUNE STATUS IN TUMOR-BEARING PATIENTS

12:00  
D. Avram  
MODULATION OF Th2 TOWARDS Th1 CYTOKINE PROFILES BY FLAVANOIDs IN PATIENTS WITH ALLERGIC ASTHMA

10.30-12.15  
Cytokines in sepsis and toxic shock  
J. Penninger  
CHAIRPERSON  
J. Doly  
CHAIRPERSON

10:55  
R. Kaempfer  
SUPERANTIGEN ANTAGONIST BLOCKS Th1 CYTOKINE GENE INDUCTION AND LETHAL SHOCK

11.20  
P. Brouckaert  
PROTECTION AGAINST TNF-INDUCED LETHAL SHOCK BY SOLUBLE GUANYLATE CYCLASE INHIBITION REQUIRES FUNCTIONAL NITRIC OXIDE SYNTHASE-2

11.35  
P. Ghezzi  
N-ACETYLCysteine (NAC) AUGMENTS MIGRATION OF NEUTROPHILS TO THE SITE OF INFECTION BUT NOT THAT TO THE LUNG: GLUTATHIONE MODULATION OF NATURAL IMMUNITY VERSUS ARDS IN SEPSIS

11.50  
J. Louahed  
INTERLEUKIN-9 CONTRIBUTES TO ALLERGIC INFLAMMATORY DISEASE BY INDUCING MUCUS PRODUCTION IN THE AIRWAYS

12.05  
M. Lebre  
MODULATION OF DENDRITIC CELL FUNCTION BY ACTIVATED KERATINOCYTES.

12.15-13.45  
Lunch/ Postersession

13.45-15.30  
Parallel symposia:

13.45-15.30  
Cytokine and interferon gene regulation I  
P. Lengyel  
CHAIRPERSON  
J. Vilcek  
CHAIRPERSON

13.45  
K. Ozato  
ICSBP (IRF-8) IS AN ESSENTIAL ACTIVATOR OF IL-12p40 TRANSCRIPTION AND REGULATES CYTOKINE EXPRESSION IN MACROPHAGES
14.10 J. Hiscott
TRANSCRIPTIONAL REGULATION OF CHEMOKINE AND INTERFERON GENE EXPRESSION BY NF-κB AND IRF FACTORS

14.35 B. Tudor Mihaei
INDUCIBLE EXPRESSION OF IκBα REPRESSOR MUTANTS INHIBITS EXPRESSION OF CYTOKINE AND APOPTOTIC GENES IN JURKAT T CELLS

14.50 S. Marecki
IRF PROTEINS AND PU.1 SYNERGIZE TO MEDIATE TRANSCRIPTIONAL ACTIVATION OF THE HUMAN INTERLEUKIN 1B GENE VIA AND UPSTREAM ENHANCER ELEMENT

15.05 P. Pitha-Rowe
MULTIPLE GATEKEEPERS REGULATE IRF ACTIVITY IN THE EARLY INFLAMMATORY RESPONSE

15.20 G. Fantuzzi
ROLE OF IRF-1 IN THE REGULATION OF IL-18 PRODUCTION, RELEASE AND BIOACTIVITY

13.45-15.30 New/second generation interferons and cytokines I

K. Zoon CHAIRPERSON
H. Schellekens CHAIRPERSON

13.45 L. Blatt
SECOND GENERATION INTERFERONS AND CYTOKINE: ENGINEERED EVOLUTION AND THERAPEUTIC OPTIMIZATION

14.10 P. Patten
EVOLUTION OF PROTEIN PHARMACEUTICALS USING DNA SHUFFLING™

14.25 J. Ryff
PRE-CLINICAL DEVELOPMENT OF PEG-ALPHA INTERFERON FOR TREATMENT OF HEPATITIS-C

14.40 J. Thèze
THE FIRST α HELIX OF IL-2 FOLDS AS AN HOMOTETRAMER, ACTS AS AN AGONIST OF THE IL-2 RECEPTOR β CHAIN AND INDUCES LYMHPHOKINE-ACTIVATED KILLER CELLS

14.55 A. Gurney
IL-21, A NOVEL HUMAN CYTOKINE THAT SIGNALS THROUGH THE INTERFERON RECEPTOR RELATED PROTEINS CRF2-4 AND IL-21R

15.10 J. Parrish-Novak
INTERLEUKIN 21; A NOVEL T-CELL DERIVED CYTOKINE THAT PROMOTES NK CELL EXPANSION AND REGULATES PROLIFERATION OF MATURE B AND T CELLS

15.20 B. Nardelli
IFN-κ, A NOVEL TYPE I INTERFERON

15.40 J. H. Bream
IDENTIFICATION OF AN IL-2 RESPONSIVE ELEMENT IN THE HUMAN IFN-γ PROMOTER

16.00-17.50 Parallel workshops:

16.00-17.40 Cytokine and interferon gene regulation II
D. Wallach CHAIRPERSON
J. Vilcek CHAIRPERSON

16.0 K. Muegge
CONTROL OF CHROMATIN ACCESSIBILITY FOR V(D)J RECOMBINATION BY IL-7

16.25 M.F. Shannon
CHROMATIN REMODELLING ACROSS CYTOKINE GENE PROMOTERS IS AN ESSENTIAL STEP IN TRANSCRIPTION

16.40 J. H. Bream
IDENTIFICATION OF AN IL-2 RESPONSIVE ELEMENT IN THE HUMAN IFN-γ PROMOTER

16.55 R. Lu
REGULATION OF PROMOTER ACTIVITY OF THE INTERFERON REGULATORY FACTOR 7 GENE

17.10 R. Kaempfer
A NOVEL ROLE FOR PKR IN CONTROL OF MRNA SPLICING

17.25 F. Bollig
INTERLEUKIN-1 AND UV-LIGHT INDUCE mRNA STABILIZATION THROUGH DIFFERENT SIGNALING MECHANISMS

16.00-17.40 New/second generation interferons and cytokines II

K. Zoon CHAIRPERSON
H. Schellekens CHAIRPERSON

16.0 R. Kastelein
A NOVEL COMPOSITE CYTOKINE FACTOR WITH BIOLOGICAL ACTIVITIES SIMILAR AS WELL AS DISTINCT FROM IL-12

16.25 J. Glaspy
THE DEVELOPMENT OF A NOVEL CYTOKINE TO PREVENT SEVERE NEUTROPENIA ASSOCIATED WITH CHEMOTHERAPY

16.40 J. Ryff
PEGYLATED INTERFERON-α 2a: APPLICATION OF BASIC SCIENCE TO THE CLINIC

16.55 L.D. Dumoutier
IL-TIF STIMULATES ACUTE PHASE REACTANT PRODUCTION BY HEPATOCYTES THROUGH IL-10Rβ
17.10 E. Dunn
BIOINFORMATIC ANALYSIS OF FIVE GENE SEQUENCES PREDICTED TO ENCODE NOVEL IL-1-LIKE CYTOKINES

17.25 C. Geczy
S100 PROTEINS: A NEW CLASS OF CHEMOTACTANTS, PROPERTIES OF HUMAN S100A12

16.00-17.50 Receptor-ligand interactions
S. Pestka CHAIRPERSON
J. Tavernier CHAIRPERSON

16.0 C. Figdor
DENDRITIC CELL ADHESION MOLECULES AND CYTOKINES

16.25 M. Tateyama
CORRELATION OF SOLUBLE IFN-α/β RECEPTOR IN SERUM OF ALZHEIMER PATIENTS AND THEIR DISEASE STAGE

16.40 H. Schmeisser
CORRELATION OF RECEPTOR FOR BINDING ACTIVITY AND ANTI-PROLIFERATIVE ACTIVITY WITH RESIDUAL 86 OF HUMAN IFN-α

16.55 M.W. Walter
STRUCTURE AND FUNCTION OF A MONOMERIC INTERLEUKIN 10

17.10 D. Yang
LINKAGE OF HOST INNATE DEFENSE AND ADAPTIVE IMMUNITY BY HUMAN ANTIMICROBIAL PEPTIDES: IDENTIFICATION OF RECEPTORS FOR HUMAN β-DEFENSINS AND LL-37

17.20 S.M. Hurst
CHEMOKINE EXPRESSION BY IL-6 AND ITS SOLUBLE RECEPTOR: ASSIGNMENT OF DISTINCT BIOLOGICAL ACTIVITIES TO THE SOLUBLE IL-6 RECEPTOR (sIL-6R) ISOFORMS

17.30 S.K. Pfanz
TWO DIFFERENT EPITOPES OF THE SIGNAL TRANSDUCER GP130 SEQUENTIALLY COOPERATE UPON INTERLEUKIN-6-INDUCED RECEPTOR ACTIVATION

17.40 G. Elson
CYTOKINE-LIKE FACTOR-1 ASSOCIATES WITH CARDIOTROPHIN-LIKE CYTOKINE TO FORM A FUNCTIONAL HETEROmeric LIGAND FOR CNTF RECEPTOR COMPLEX.

18.00-19.45 Award Ceremonies
R. Kaempfer CHAIRPERSON

Tuesday November 7

8.30-10.00 Review Lectures:
J.M. Dayer CHAIRPERSON
D. Golenblock

8.30 D.R. Ransohoff
UNDERSTANDING MULTIPLE SCLEROSIS: THE OUTLOOK FOR NOVEL THERAPEUTICS BASED KNOWLEDGE

10.00-10.30 Coffee Break

10.30-12.15 Parallel workshops:
B. Williams CHAIRPERSON
K. Ozato CHAIRPERSON

10.30 A.T. Takaoka
NOVEL CROSS-TALK MECHANISM BETWEEN TYPE I AND TYPE II INTERFERON RECEPTORS

10.45 M.P. Gil
IDENTIFICATION OF A NOVEL PHYSIOLOGICALLY-RELEVANT STAT1-INDEPENDENT IFNγ RECEPTOR (IFNγR) SIGNALING PATHWAY

11.0 L.P. Pfeffer
IFNα/β PROMOTES CELL SURVIVAL BY ACTIVATING NF-kB

11.15 C.M. Horvath
INTERFERON REGULATORY FACTOR (IRF) SUBCELLULAR LOCALIZATION IS DETERMINED BY A BIPARTITE NLS IN THE DNA BINDING DOMAIN AND INTERACTION WITH CYTOPLASMIC RETENTION FACTORS

11.30 K. Roy
A NOVEL INTERFERON-γ STIMULATED GENE REGULATORY PATHWAY

MEDIATED BY CAAT/ENHANCER BINDING PROTEIN-BETA (C/EBP-β) AND EXTRACELLULAR SIGNAL REGULATED KINASES

11.45 D.W. Wald
SIMILARITIES AND DIFFERENCES IN SIGNALING PATHWAYS THAT RESPOND TO IL-18 AND IL-1

10.30-12.15 Clinical use of cytokines and interferons
Kendall Smith CHAIRPERSON
T. Calandra CHAIRPERSON

10.30 K. Smith
IN VIVO ANTIVIRAL REACTIVITY IN CHRONIC HIV INFECTION

10.55 M. Feldmann

11.20 C. Van Montfrans
THERAPEUTIC POTENTIAL OF GENETICALLY MODIFIED T LYMPHOCYTES IN CROHN'S DISEASE

11.35 P. Rendo
THERAPY WITH α-INTERFERON INDUCES IMPROVEMENT OF PLATELET COUNTS IN CHILDREN WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA

11.50 J. Fernández
PREDICTIVE FACTORS OF SUSTAINED RESPONSE TO INTERFERON ALFA 2b AND RIBAVIRIN THERAPY FOR CHRONIC HEPATITIS C

12.05 S. Balachandran
INTERFERON CAN SENSITIZE CELLS TO VIRAL-INDUCED APOPTOSIS BY MODULATING THE ACTIVITY OF THE DEATH-INDUCED SIGNALING COMPLEX (DISC).

12.15 Functional polymorphism of cytokine genes
L. Aarden CHAIRPERSON
B. Lebleu CHAIRPERSON

10.30 G. Duff

10.55 C. Verweij

11.20 M. Shahbazi
FUNCTIONAL POLYMORPHISMS IN GROWTH FACTORS (EGF, PDGF-BB, VEGF)
11.35 A. Goris
LINKAGE DISEQUILIBRIUM ANALYSIS OF THE IFN-γ CHROMOSOMAL REGION IN SARDINIAN SIMPLEX FAMILIES WITH MULTIPLE SCLEROSIS

11.50 C.T.J. Holweg
THE DINUCLEOTIDE REPEAT POLYMORPHISM IN THE 3 FLANKING REGION OF THE IL-2 GENE IS ASSOCIATED WITH FREEDOM FROM ACUTE REJECTION

12.05 F.J. Bijlsma
IL-4 PROMOTER GENE POLYMORPHISM IN HEART TRANSPLANTATION

12.15-13.45 Lunch/Postersession

13.45-15.40 Parallel symposia:

13.45-15.00 Signal transduction II
B. Williams CHAIRPERSON
K. Ozato CHAIRPERSON

13.45  D. Levy
THE VARIED ROLES OF STAT3, FROM ANTI-INFLAMMATORY ACTION TO ONCOGENESIS

14.00 N.C. Reich
NUCLEAR EXPORT OF THE STAT1 TRANSCRIPTION FACTOR

14.15 B.H. Lillemoeier
MECHANISM OF CYTOPLASMIC TRANSLLOCATION OF STAT1: PHOTOBLEACHING ANALYSIS OF STAT1-GFP

14.30 H.A.Q. Nguyen
TRANSCRIPTIONAL SYNERGY BETWEEN IFNγ AND IL10 OR TNF: ROLES OF STAT1 SERINE PHOSPHORYLATION AND IFNγ-ACTIVATED PHOSPHATIDYLINOSITOL-3-KINASE

14.45 R. Bordens
QUANTIFICATION OF STAT NUCLEAR TRANSLLOCATION IN INTRON A STIMULATED HELA CELLS USING AN AUTOMATED FLUORESCENT IMAGING SYSTEM

15.05 A.M. Gamero
ERK5: A MAP KINASE ACTIVATED BY IFNα THAT PHOSPHORYLATES STAT1

15.15 M. Paulson
INTERFERON INDUCED GENE ACTIVATION UTILIZES HISTONE AND STAT2 ACETYLYATION AND THE COMPONENTS OF TBP FREE TAF CONTAINING COMPLEX (TFTC)

15.45-15.50 Type I interferons: Selective signalling and effects on the nervous system
W. Jones CHAIRPERSON

15.50 T. Olsson
CYTOKINES AND NEUROTROPHINS IN NEUROINFLAMMATION; IMPACT OF NON-MHC GENETIC REGULATION

16.05 M.R. Rani
A ROLE FOR NF-κB IN THE INDUCTION OF CHEMOKINE CXCL11 BY IFN-γ

16.15 J.E. Angell
CHARACTERIZATION OF A NOVEL DEATH REGULATORY GENE INVOLVED IN INTERFERON-8 AND RETINOIC ACID INDUCED CELL DEATH

16.30 I. Fidler
REGULATION OF ANGIGENESIS BY INTERFERON TYPE 1

16.45 I. Lillemeier
CELL SURFACE-EXPRESSED MOESIN REGULATES T CELL INTERACTIONS WITH TISSUE COMPONENTS AND BINDS ADHESION-MODULATING IL-2 PEPTIDES GENERATED BY ELASTASE

17.00 M. Guthridge
SITE-SPECIFIC SERINE PHOSPHORYLATION OF THE IL-3 RECEPTOR IS REQUIRED FOR HEMOPOIETIC CELL SURVIVAL

17.15 L.M. Ching
IP-10 INDUCTION AND INHIBITION OF ANGIogenesis BY THE ANTITUMOR AGENT 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID (DMXAA)

17.30 Q.E. Low
WOUND HEALING IN MIP-1α/− AND MCP-1−/− MICE

17.45 M.A. Horisberger
MxA AND ß-DEFENSIN-2, TWO ANTI-INFECTIVE PROTEINS INDUCIBLE BY IFNα/β AND CYTOKINES, RESPECTIVELY, ARE CONSTITUTIVELY EXPRESSED IN MUCOSA AND UPREGULATED IN LESIONAL AND HEALING SKIN

18.00-18.00 Teabreak/Postersession

18.00-18.45 Parallel workshops:

18.00-18.45 Interferon-inducible proteins (includes PKR)
A.G. Hovanessian CHAIRPERSON
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>M.J. De Veer</td>
</tr>
<tr>
<td>16.15</td>
<td>N. Barber</td>
</tr>
<tr>
<td>16.30</td>
<td>A.S. Lau</td>
</tr>
<tr>
<td>16.45</td>
<td>M. Esteban</td>
</tr>
<tr>
<td>17.00</td>
<td>J. Gil</td>
</tr>
<tr>
<td>17.30</td>
<td>E. Borden</td>
</tr>
<tr>
<td>17.45</td>
<td>M. Rubinstein</td>
</tr>
<tr>
<td>18.00</td>
<td>B.R.C. Lebleu</td>
</tr>
<tr>
<td>18.30</td>
<td>A. Roberts</td>
</tr>
<tr>
<td>18.45</td>
<td>T. Patel</td>
</tr>
<tr>
<td>19.00</td>
<td>A. van Deventer</td>
</tr>
<tr>
<td>19.15</td>
<td>F. Melchers</td>
</tr>
<tr>
<td>19.30</td>
<td>J. Van Damme</td>
</tr>
<tr>
<td>19.45</td>
<td>R. Strieter</td>
</tr>
<tr>
<td>20.00</td>
<td>F. van Deventer</td>
</tr>
<tr>
<td>20.15</td>
<td>R. van Deventer</td>
</tr>
<tr>
<td>20.30</td>
<td>R. van Deventer</td>
</tr>
</tbody>
</table>

**Wednesday November 8**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30</td>
<td>F. Melchers</td>
</tr>
<tr>
<td>9.15</td>
<td>B. Williams</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Parallel workshops:</td>
</tr>
<tr>
<td>10.30</td>
<td>Chemokines</td>
</tr>
<tr>
<td>10.55</td>
<td>J. Van Damme</td>
</tr>
<tr>
<td>11.20</td>
<td>A. Richmond</td>
</tr>
<tr>
<td>11.50</td>
<td>R. Krzysiek</td>
</tr>
<tr>
<td>12.05</td>
<td>S.A. Jones</td>
</tr>
<tr>
<td>8.30</td>
<td>Review Lectures:</td>
</tr>
<tr>
<td>9.15</td>
<td>B. Williams</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Parallel workshops:</td>
</tr>
<tr>
<td>10.30</td>
<td>Chemokines</td>
</tr>
<tr>
<td>10.55</td>
<td>J. Van Damme</td>
</tr>
<tr>
<td>11.20</td>
<td>A. Richmond</td>
</tr>
<tr>
<td>11.50</td>
<td>R. Krzysiek</td>
</tr>
<tr>
<td>12.05</td>
<td>S.A. Jones</td>
</tr>
</tbody>
</table>

International Society for Interferon and Cytokine Research
G. McFadden CHAIRPERSON

10.30  H. Holtmann
CONTROL OF CYTOKINE mRNA TURNOVER BY STRESS SIGNALING PATHWAYS

10.55  M. Kracht
THE MAPKKK TAK1 PLAYS A CENTRAL AND NON-REDUNDANT ROLE IN COUPLING THE IL-1 RECEPTOR TO BOTH TRANSCRIPTIONAL AND RNA-TARGETTED MECHANISMS OF GENE REGULATION

11.10  R. Kishore
MODULATION OF AN AU-RICH ELEMENT BINDING ACTIVITY BY IL-10 IN MOUSE MACROPHAGES

11.25  S. Saccani
INCREASED INTERLEUKIN-10 mRNA STABILITY IN MELANOMA CELLS: VIRUS INFECTED NORMAL MELANOCYTES IS FUNCTIONALLY ASSOCIATED WITH DECREASED LEVELS OF A+U-RICH ELEMENT BINDING FACTORS

11.40  G. Brewer
ALTERED PHOSPHORYLATION OF AUF1 AND MODULATION OF CYTOKINE mRNA DECAY IN MONOCYTES

11.55  J.L.E. Dean
HuR BINDS THE AU-RICH REGION OF TNF-α mRNA AND ITS OVEREXPRESSION STABILIZES A TNF-α mRNA REPORTER

12.05  K. Mahtani
THE EXPRESSION OF TRISTETRAPROLIN IS REGULATED BY THE MITOGEN ACTIVATED PROTEIN KINASE p38 SIGNAL TRANSDUCTION PATHWAY

12.15-13.15  Cytokines and interferons in transplantation
T. Kishimoto CHAIRPERSON
M. Goldman CHAIRPERSON

12.30  M. Goldman
EFFECTOR MECHANISMS OF ALLOGRAFT REJECTION: A ROLE FOR TH2-TYPE RESPONSES

12.55  C. Baan
CYTOKINE GENE POLYMORPHISMS IN ORGAN FAILURE AND AFTER ORGAN TRANSPLANTATION

11.20  M. Braun
INTERLEUKIN-9 TRIGGERS ACUTE EOSINOPHILIC REJECTION OF HEART ALLOGRAFT IN MICE

11.35  N.M. Van Besouw
THE FREQUENCY OF IL-2 PRODUCING T-LYMPOCYTES PREDICTS ACUTE REJECTIONS AFTER TRANSPLANTATION EVEN BEFORE TRANSPLANTATION

11.45  I.C. Van Riemsdijk
CONVERSION FROM CYCLOSPORINE TO TACROLIMUS DOWN REGULATES THE TGF-β SYSTEM AND IMPROVES RENAL FUNCTION, CHOLESTEROL LEVELS AND BLOOD PRESSURE IN HEART TRANSPLANT RECIPIENTS

12.05  V. Barak
ELEVATED IL-18 AND IL-18 BP LEVELS IN ACUTE GVHD POST ALLO SCT.

12.15-13.45  Lunch/ Postersession

13.45-15.30  Mode of action of cytokines I
C. Dinarello CHAIRPERSON
N. Ruddle CHAIRPERSON

13.45  A. Billiau
THE BIMODAL EFFECT OF ENDOGENOUS IFN-γ IN MURINE MODELS OF AUTOIMMUNE DISEASE: A ROLE FOR MYCOBACTERIAL ADJUVANT-INDUCED MYELOPOIESIS

14.10  D.V. Kalvakolanu
IDENTIFICATION AND CHARACTERIZATION OF THE NOVEL GENES ASSOCIATED WITH RETINOIC ACID-INTERFERON INDUCED MORTALITY (GRIM), USING A GENETIC APPROACH: MECHANISM OF ACTION AND ROLE IN TUMOR CELL GROWTH SUPPRESSION BY CYTOKINES

14.25  J. Hu
INTERLEUKIN-6 MODULATES INTERFERON-REGULATED GENE EXPRESSION BY INDUCING THE ISGF3γ GENE USING CCAAT/ENHANCER BINDING PROTEIN-BETA (C/EBP-8)

14.40  N. Benbernou
IL-7 STIMULATES TYROSINE PHOSPHORYLATION OF CLATHRIN WHICH IS CONSTITUTIVELY ASSOCIATED WITH THE IL-7Rα CHAIN.

14.55  A. Battistini
PIVOTAL ROLE OF THE IRF-1 TRANSCRIPTION FACTOR IN G-CSF-INDUCED GRANULOCYTIC DIFFERENTIATION

15.10  K. Cardozo
IDENTIFICATION OF NOVEL IL-1β-INDUCED GENES IN PANCREATIC β-CELLS BY HIGH DENSITY OLIGONUCLEOTIDE ARRAYS

15.20  W. Jelkmann
HYPOXIA-INDUCIBLE FACTOR 1, A NOVEL TRANSCRIPTIONAL MEDIATOR OF IL-1 AND TNF-α EFFECTS

13.45-15.30  Signal transduction II
B. Williams CHAIRPERSON
K. Ozato CHAIRPERSON

13.45  W. Schrader
RPM, smgGDS AND M-RAS: NOVEL RAS PATHWAYS

14.0  L.C. Platanias
ACTIVATION OF THE RAC1/P38 MAP KINASE PATHWAY BY TYPE 1 IFNS REGULATES TRANSCRIPTIONAL ACTIVATION VIA SERINE PHOSPHORYLATION OF HISTONE H3

14.15  X.X. Li
FUNCTION OF IRAK IN IL-1β SIGNALING AND IDENTIFICATION OF ACT1, A NOVEL NFκB-ACTIVATING PROTEIN

14.30  C.M.U. Hilkens
JAK1 INTERACTS WITH GP130 THROUGH ITS FERM DOMAIN

14.45  M. Algarté
NEW TYK2 PARTNERS IDENTIFIED BY A YEAST TWO-HYBRID SCREEN

15.0  J. Bernhagen
JAB1 IS AN ACTIVATING PROTEIN FOR THE CYTOKINE MIF: MODULATION OF AP-1 ACTIVITY AND CELL CYCLE PATHWAYS

International Society for Interferon and Cytokine Research 7
15.15 S. Verploegen
IDENTIFICATION AND
CHARACTERISATION OF CKLIK A
NOVEL GRANULOCYTE
Ca\(^{2+}\)/CALMODULIN-DEPENDENT
KINASE

13.45-15.30 Oral/nasal interferons and
cytokines
W. Beilharz CHAIRPERSON
S. Brod CHAIRPERSON

13.45 M.G. Tovey
OROMUCOSAL INTERFERON
THERAPY: MECHANISM(S) OF
ACTION

14.0 S. Brod
INGESTED IFN-\(\alpha\) DECREASES NEW
MRI BRAIN LESIONS IN
RELAPSING-REMITTING
MULTIPLE SCLEROSIS (RRMS).

14.15 M. Beilharz
LOW DOSE ORAL INTERFERON
THERAPY: TOWARDS A
MECHANISM OF ACTION

14.30 I.L. Villarete
CYTOKINE REGULATION IN
HUMANS AND IN MICE AFTER
ORAL TREATMENT WITH
INTERFERON-TAU

14.45 A.N. Nakajima
GASTRIC ADMINISTRATION OF
ovIFN CAN INDUCE BLOOD
2',5'-OLIGOADENYLATE
SYNTHETASE IN MOUSE

15.0 C. Sletteberg
IMMUNOMODULATION AND
TUMOUR CYTOTOXICITY IN MICE
PRESENTED ORALLY WITH PLANT
LECTINS.

15.15 G. Sonnenfeld
LACK OF PROTECTION OF MICE
FROM LETHAL INFECTION USING
ORAL (SUBLINGUAL OR
INTRANASAL) APPLICATION OF
INTERFERON-\(\alpha\) (IFN-\(\alpha\))

15.30-16.00 Teabreak/ Postersession

16.00-17.45 Mode of action of
interferons
O. Haller CHAIRPERSON
K. Muegge CHAIRPERSON

16.0 R.H. Silverman
MODE OF RNASE ACTIVATION: AN
IFN REGULATED ANTIVIRAL

ENZYME RELATED TO THE
UNFOLDED PROTEIN RESPONSE
PROTEIN, IRE1

16.15 J. da Silva
DIFFERENTIAL ACTIVATION OF
THE COMMON IFNAR1/IFNAR2
RECEPTOR COMPLEX BY
INTERFERON SUBTYPES: A
COMPREHENSIVE ANALYSIS OF
GENE EXPRESSION

16.30 E. Pattyn
STUDY OF TYPE 1 INTERFERON
SIGNALLING USING CHIMERIC
RECEPTORS

16.45 S. Erickson
INTERFERON-\(\alpha\) DOWNREGULATES
TELOMerase REVERSE
TRANSCRIPTASE AND
TELOMerase ACTIVITY IN
HUMAN MALIGNANT AND NON-
MALIGNANT HEMATOPOIETIC
CELLS

17.0 P. Subramaniam
LIGAND-MEDIATED NUCLEAR
CHAPERONING OF STAT1\(\alpha\): THE
IFN\(\gamma\) PARADIGM

17.15 M. Brierley
AN OBLIGATORY AND ISGF3-
INDEPENDENT ROLE FOR STAT2 IN
INTERFERON-INDUCED
ANTIPROLIFERATIVE RESPONSES

17.30 B. Henzgen
MECHANISMS OF THE DIVERSE
ANTI-TUMOR EFFECTS OF TUMOR
CELL-ASSOCIATED IL-1 ALPHA
AND IL-1 BETA

16.00-17.40 Chemokines, HIV and
vaccine
J. van Damme CHAIRPERSON
C. Ware CHAIRPERSON

16.0 T. Lehner
CHEMOKINES, CHEMOKINE
RECEPTORS AND HIV OR SIV
VACCINATION

16.25 A.G. Hovanessian
INHIBITION OF HIV INFECTION BY
THE CYTOKINE MIDKINE

16.40 B. Sherry
\(\beta\) CHEMOKINE EXPRESSION
DOWNREGULATED BY HIV-1
THROUGH A TGF-B-DEPENDENT
MECHANISM

16.55 M.M. Mengozzi
THE STRENGTH OF CD28
COSTIMULATION DETERMINES
ENHANCEMENT OR INHIBITION OF
R5 HIV REPLICATION

17.10 A. Kalinkovich
ELEVATED EXPRESSION OF \(\beta\)-
CHEMOKINE RECEPTORS:
RELEVANCE TO THE INCREASED
SUSCEPTIBILITY TO HIV
INFECTION IN AFRICA?
A. Foussat
Deregulation of the expression of the fractalkine/fractalkine receptor complex related to viral replication in HIV-1-infected patients

Thursday November 9

8.30-10.45 Review lectures:
K. Zoon CHAIRPERSON

8.30 W.E.G. Mueller
Evolution of cytokines: identification and possible function in the phylogenetically oldest metazoans the sponges

9.15 J. Penninger

10.0 E.C. Borden
Interferons and cancer 2000: where from here?

10.45-11.15 Coffee break

11.15-13.00 Parallel workshops:

11.15-13.00 Interferons and cytokines in infectious disease I
F. Bonino CHAIRPERSON
P. López-Saura CHAIRPERSON

11.15 P. Staeheli
cDNA cloning of biologically active chicken interferon-18

11.30 R. Deonarain
Phenotype of IFN-β null-mutant mice: immune status

11.45 E. Durbin
PKR protection against intranasal vesicular stomatitis virus infection is mouse strain dependent

12.00 J. Bucala
Circadian relationship between cortisol and macrophage inhibitory factor (MIF): evidence for a neuro-endocrine interaction

12.15 J. Fernández
Therapy with interferon alfa 2b and ribavirin in naive patients with chronic hepatitis C

12.30 C.L. Civitano
A novel dynamic equation to represent and study virus-host interactions in HCV infected patients

12.45 F. Dianzani
Predictive markers of response to interferon α in hepatitis C patients

11.15-13.00 Mode of action of cytokines II
C. Dinarello CHAIRPERSON
N. Ruddle CHAIRPERSON

11.15 O. Haller
Human MxA protein associates with LaCrosse virus nucleoprotein and prevents its accumulation in the Golgi compartment

11.30 C.E. Samuel
Interferon-inducible double-stranded RNA-specific adenosine deaminase (ADAR1): novel regulation by interferon and editing of glutamate and serotonin receptor pre-mRNAs

11.45 N. Cha
Immune response in Stat2 knockout mice

12.0 E.N. Fish
Ccr5: a signaling scaffold regulated by rantes, myxoma virus and Rgs-6

12.15 M. Karaghiosoff
Compromised adaptive and innate immune responses in tyk2-deficient mice

12.30 J.E. Chebath
Extinction of melanogenesis and expression of glial cell markers in f10.9 melanoma treated with ril6

12.45 W.C. Au
Induction of human endogenous Ifnα genes requires IRF-7 and IRF-3.

11.15-13.00 Cytokines and interferons in autoimmunity
J. van der Meer CHAIRPERSON
A. Schimpl CHAIRPERSON

11.15 G. Kollias

11.40 C.K. Edwards
Effects of PEG sTNF-RI, IL-1ra, or the combination in TNF-α knockout mice expressing a mutant transgenic form of murine transmembrane TNF-α

11.55 M. Nicklin
Inflammatory diseases in IL-1 receptor antagonists-deficient mice

12.10 E.M. Crawley
There is a genetic predisposition to low IL-10 production in children with extended oligoarticular juvenile idiopathic arthritis

12.25 A.S.K. De Hooge
Enhanced suppression of cytokine signaling in inflamed synovia from IL-6 deficient mice resistant to developing chronic arthritis

12.40 B. Siegmund
Neutralization of IL-18 exerts anti-inflammatory activity in experimental colitis in mice

12.45 D. Neumann
DNA vaccination against IL-18 decreases autoimmune alterations and prolongs survival in murine lupus

13.00-13.45 Lunch

13.45-15.30 Parallel workshops:

13.45-15.30 Toll and apoptosis
L. Aarden CHAIRPERSON
D. Golenblock CHAIRPERSON

14.10 A. Khaleed
Trophi factor withdrawal induces a novel pathway: p38 mark activates NHE1 resulting in intracellular alkalination, an early step in apoptosis

14.20 M.T. Harte
Characterisation of the interaction of the vaccinia virus proteins A46R and A52R with mediators of IL-1/toll signaling
14.30 M.J. Fenton
AN ANTAGONIST TOLL-LIKE
RECEPTOR 4 (TLR4)
DIFFERENTIALLY BLOCKS M.
TUBERCULOSIS-INDUCED
MACROPHAGE RESPONSES

14.40 S. Landolfo
THE RETINOBLASTOMA PROTEIN
IS AN ESSENTIAL MEDIATOR THAT
LINKS THE HUMAN HIN 200 AND
MOUSE HOMOLOGUE Ifi 200 GENES
TO CELL-CYCLE REGULATION

14.50 R.D. Rebouillat
EXPRESSION OF THE LARGE FORM
OF HUMAN 2',5'-
OLIGOADENYLATE
SYNTHETASE DOES NOT CONFER
ANTIVIRAL ACTIVITY BUT
CONFERS SENSITIVITY TO Pic-
INDUCED APOPTOSIS.

15.00 E.J. Kovacs
IMPROVED SURVIVAL AND
IMMUNITY IN INTERLEUKIN-6 (IL-
6) DEFICIENT MICE SUBJECTED TO
BURN TRAUMA

15.10 Y. He
HCV NS5A NONSTRUCTURAL
PROTEIN PERTURBS MULTIPLE
SIGNALING PATHWAYS BY
TARGETING GRB2 ADAPTOR
PROTEIN AND GAB1 SIGNALING
COMPLEX

16.00- 17.00 Closing Session
M.J. Fenton CHAIRPERSON
J. Oppenheim CHAIRPERSON

Support the
ISICR!
Renew Your
Membership
Now!

Students and
Postdoc ISICR
Membership
Dues are only
$10

Thought to Ponder
Our eyes are always the same
size from birth, but our nose
and ears never stop growing
New ISICR Members

The ISICR welcomes the following new members. Contact information can be obtained from the Headquarters Office

Michele Algarte
Paris, France
Betsy Jo Barnes
Baltimore, MD
Claudia Ida Brodsky
Salvador, Bahia, Brazil
Siska M. Brutsaert
New York, NY
Edward N. Cha
New York, NY
Jacques Couderc
Clamart, France
Daniele Decanine
Salvador-BA, Brazil
Ana M. Gamero
Cleveland, OH
Pierre Genin
Montreal, Quebec, Canada
Athena Giannoudis
Sheffield, UK
An A.E. Goris
Leuven, Belgium
Marie Green
Cambridge, MA
Brock Grill
Vancouver, BC, Canada
Sharon Hashmueli
Haifa Israel
Yupeng He
Seattle, WA
Junbo Hu
Baltimore, MD
Ge Jin
Cleveland, OH
Michael H. Kogut
College Station, TX
Ahmed Lasfar
Piscataway, NJ

Susumu Nakae
Tokyo, Japan
Gioacchino Natoli
Bellinzona, Switzerland
Miguel-Angel Perales
New York, NY
Gregory A. Peters
Cleveland, OH
Arun Prakash
New York, NY
Lewis Joseph
Radonovich
Baltimore, MD
W.L. Ragland, III
Zagreb, Croatia
Sanjit Kumer Roy
Baltimore, MD
Hana Schmeisser
Kensington, MD
Gregory S. Schreiber
St. Louis, MO
Marc Servant
Montreal, Quebec, Canada
Helena Yin Yee Sim
Clayton, Victoria, Australia
Eric James Smith
New York, NY
Kendall A. Smith
New York, NY
Prem S. Subramanian
Gainesville, FL
Thayne Lyle Sweeten
Indianapolis, IN
Akinori Takaoka
Tokyo, Japan
David Nathan Wald
Cleveland, OH

Students and Fellows
Science of the Future

Women Issues - Part 2.

Women*s Issues * Part II

In my last column, I had posted a survey questioning the "existence" of women*s issues in interferon and cytokine research, or biomedical research in general. In this issue, the opinions of several women scientists are presented. As you will see, the responses are varied. I think that the individual comments are particularly important, since the purpose of the survey is not to point fingers or assess blame, but to make aspiring women scientists aware of what may lie ahead. From this exercise, I learned that whether or not women are treated fairly in biomedical research is not a black-and-white situation and depends on many, many factors which may vary from institution to institution, or even vary individually. It seems as well that gender inequality is not as relevant at the level of graduate school or postdoctoral work; the number of women versus men in graduate school or postdoctoral work are more-or-less equal, and female graduate students or postdocs are further encouraged by the existence of research awards. These facts probably explain why I, as a postdoc and probably many others like myself do not feel gender-biased at this particular
stage of our career. On the other hand, women issues seem more likely to occur at the level of faculty or higher status positions. A very helpful colleague referred me to two very interesting web articles which describe the status of gender fairness and how it is being dealt with at the Massachusetts Institute of Technology (MIT), found at http://news.bmn.com/hmsbeagle/56/notes/adapt, and http://web.mit.edu/fnl/women/Fnlwomen.htm. Also, for those interested, the ISICR annually addresses women's issues via a seminar which is held during the course of the ISICR Meeting.

So here are some of the responses from several women scientists in our field. Two have agreed to leave their name, they are Dr. Eleanor Fish, Associate Professor, Dept. of Immunology, Faculty of Medicine, University of Toronto, and Head, Division of Cell & Molecular Biology, Toronto General Research Institute; and Dr. Keiko Ozato, Deputy Chief, Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, National Institutes of Health. Others have chosen to remain anonymous; I’ve labeled them A1, A2 or A3. I would like to thank them for their time and the courage to "speak out" for the benefit of future women scientists.

1. Do you think that the interferon/cytokine field is male-dominated?
E.F.: YES, YES, YES
K.O.: Generally Yes. However, the ISICR, as a society, has been leading in the effort to equalize gender gaps.
A1: No.
A2: There are more men that women, but women are represented to some extent.
A3: Sorry, but I am not convinced with the necessity of "women issues".

2. Do you think that the interferon/cytokine field reflects the general state of biomedical research? If No, how is it different?
E.F.: In part, YES. Cytokine biology impinges upon many biomedical disciplines, e.g. virology and infectious diseases, immunology (including transplantation), biochemistry, genetics, pharmacology, and many different clinical disciplines e.g. cardiology, respirology, hematology and oncology.
K.O.: Yes
A1: No, it is a much smaller group and it is very closed to the outside.
A2: Yes.

3. Do you think that "women issues" in our field is a crucial issue, or is it overrated? Why?
E.F.: Neither crucial or overrated. An issue to be addressed. Graduate studies, postdoctoral programs, functioning as a principal investigator whilst juggling family life, child raising, promotion, all these from a female perspective have unique challenges.
K.O.: It is true that in a global scale women still face a greater difficulty professionally than men. It is difficult not to acknowledge these difficulties. How to effectively address the issue is a separate question.
A1: I think it is overrated at this point. There are more practical issues that have to be addressed. Like day care, flexible time, ability to take time off, even unpaid when needed for child associated problems, lack of mentoring etc.
A2: It is important--my view is that it is not extreme.

4. Do you think that there are gender differences in the interferon/cytokine field with regard to:

a) availability of academic faculty and/or higher industrial positions
E.F.: YES
K.O.: I cannot give statistically valid evidence on these issues.
A1: not in academics
A2: Yes

b) salaries
E.F.: YES
K.O.: I cannot give statistically valid evidence on these issues.
A1: not generally
A2: no knowledge

c) ability to publish scientific papers
E.F.: NO
K.O.: I cannot give statistically valid evidence on these issues.
A1: generally not, but I am not sure about the selected journals where it is very clan oriented
A2: No

5. Do you think that any gender differences observed are due to the way women may think/act - for example, feeling inferior to men in terms of the ability to succeed, higher priority to family versus career, culture/background-related issues?
E.F.: Again, neither yes or no, not black or white. Certainly, there are women who are uncomfortable or ill at ease with assuming leadership roles in a predominantly male-dominated environment. And some women choose child rearing over a scientific career. That said, in the same way that looking sexy does not justify rape, so membership in the female community, with all the inherent ambiguities, does not justify prejudice.
K.O.: No. I believe that it is mostly due to the problem of society/politics and of human history (not long ago women had much fewer opportunities).
A1: There are number of studies done and one published book which show that people see men and women differently. What is interesting about these studies is that the difference in perception is not only by men but also by women. So I think that the questions you ask are right*
A2: Complex algorithm of all.

6. Do you think that any gender differences observed are due to "barriers" in the workplace for women compared to men? For example, are higher positions/salaries still awarded preferentially to men, regardless of qualification?
E.F.: YES - in many institutions.
K.O.: In some part of the world this barrier still exists in a blatantly discriminatory manner and in other parts in a more subtle way. But many aspects of our society (not only workplace) need to change in order to achieve real improvement.
A1: I do not think that there are many barriers today and these will diminish gradually. Salaries at least at Universities are generally comparable.
A2: Somewhat.

7. Please provide any comment regarding the above and/or advice for aspiring women scientists:
E.F.: Advice? Be passionate about who you are and why you want to do science. Then learn to multi-task. That's what women do best!
K.O.: We just keep going: change is inevitable and history is on our side. If we can, let us give a helping hand to other women, but in a fair way.
A1: 1. Have confidence in yourself; you can do it if you put your mind to it. 2. You can have career and family but focus only on important issues. Do not try to be a perfect housekeeper and scientist as well. Do not bake cookies, buy them. Do not spend hours on the telephone with other mothers, write grants. Do not cut the time with your children, but involve them in what you are doing. 3. Forget about gender issues, science is hard for everybody. Do not take everything as an insult, do not worry about small issues. 4. Get involved only in decision making committees, do not feel that you have to be part of every committee that exists. Do not cut on your research time.
A2: I think we need to encourage and support women in IFN-cytokine field.

REVIEWS OF INTEREST


Famous Fact: Leonardo Da Vinci invented the scissors

WWW

Bioinformer

http://bioinformer.ebi.ac.uk/newsletter/

EBI's newsletter about bioinformatics research (ISSN 1462-1363), development, and services at the EBI and elsewhere -- is now online.

Articles and news
o Lead article: EMBL Nucleotide Sequence Submissions: From Receipt to Distribution
o Human Proteomics Initiative: annotating and distributing highly curated information on human protein sequences
o Establishing a public repository for DNA microarray-based gene expression data at the EBI
o Standards to create clean data sets for Gene Prediction: presents methods and a ready-to-work data set
o GenomeBuilder: a Java tool to visualise and process EST assemblies
o Press release: Armchair evolution -- bioinformatics helps to redraw family tree of life.
  o External Services News from the EBI
  o Short News:
    # MRC Career opportunities in bioinformatics and neuroinformatics

Regular sections
o New staff at the European Bioinformatics Institute

o Software and databases: new products and updates
o Meeting points: worthwhile conferences and workshops
  (see also http://bioinformer.ebi.ac.uk/Events/)

Jean-Jack Riethoven -- Editor
"BioInformer"
EMBL Outstation - Hinxton
European Bioinformatics Institute

CABRI

http://www.cabri.org/ (mirrors www.cabri.org)

Common Access to Biological Resources and Information

CABRI includes 26 catalogues from some of the most known European culture collections, including BCCM, CABI, CBS, DSMZ and ECACC, for a total of more than 86,000 strains.

Organism types are fungi, yeasts, cell lines, bacteria, archaea, plasmids, DNA probes, plant cells and viruses, phages.

The CABRI search engine is based on SRS and allow for an integrated search on all the catalogues of a unique organism type.

CABRI includes a shopping cart through which end users can issue a pre-order notification to the collections.

Quality management guidelines are also available in the CABRI site.

Paolo Romano (paolo@ist.unige.it)
Biotechnology Department, Natl Inst. for Cancer Research
c/o Advanced Biotechnology Centre
Significant improvements have been made to SANBI's stackPACK EST clustering, transcript reconstruction and variation analysis tools.

The latest release of the stackPACK system, while using the same scientific schema as stackPACK 1.0, has been completely re-engineered over the past year as a focused project to provide a solid and highly robust system by Electric Genetics, in cooperation with SANBI.

We are happy to announce the release and availability of stackPACK v2.0, initially for the Linux platform with SGI, SUN and Compaq soon to follow. As the software is basically entirely revamped, it is necessary to register again. Electric Genetics are making the full commercial version of stackPACK freely available to academics.

stackPACK v2.0 differs from the initial academic release in the following ways:
- Provides a web-based interface which provides access to the clustering tools, generates output reports and provides viewing tools that link consensus sequences, alignments, splice analysis and external data sources like UniGene to assist the user in highlighting potential alternate expression forms within their clusters.
- C++ framework to manage applications and schedule processes.
- Interacts with a relational database instead of flatfiles, as in the old system, to store and manage data throughout the clustering pipeline.
- The RDB theoretically can be any ODBC compliant database - we use MySQL internally.
- Includes a CORBA interface to the data, facilitating integration between our system and external systems.

Electric Genetics will answer your technical support questions via email: support@egenetics.com

Win Hide, Director
SANBI

We have also created a mailing and discussion list, stackers@sanbi.ac.za, for clustering and transcript reconstruction discussion (see below). The list is aimed at those researchers who are attempting to analyse expression products. Receipt of this email does not mean that you are on the stackers mailing list.

Mailing List details:
Stackers can be subscribed and unsubscribed at:
http://fling.sanbi.ac.za/mailman/listinfo/stackers

Gene Expression Web site
http://dir.clubs.yahoo.com/Science/Biology/Molecular_Biology/index.html

The science/biology/molecular biology section of yahoo-clubs services has a new section for those interested in sharing and posting information relating to control of gene expression. You are invited for your input, questions and to provide answers.

Kenneth P. Mitton, PhD
kpmittton@umich.edu
ken@mitton.com
lab phone: 734-936-8370
FAX: 734-647-0228

Gene Predictions for SUPER_LINK Chromosome 22:
http://genomic.sanger.ac.uk/infodb.shtml

Under CGG genomics WEB server: http://genomic.sanger.ac.uk/

The predictions by Fgenes program (Salamov, Solovyev, 1999)

Chromosome 22 predicted genes and similarity data in INFOGENE format
Chromosome 22 predicted proteins in fasta format
Chromosome 22 predicted exon sequences in fasta format
Chromosome 22 predicted exon amino acid sequences in fasta format
Due to high accuracy exon prediction and significantly less accurate assigning exons to a particular gene, exon sequences itself present value to experimental gene verification or Other projects.

Visual representation of Predicted genes as well as ALL KNOWN GENES could be seen in gene centred database INFOGENE through Java viewer. This database includes genes constructed often from many GenBank entries, release 114.

Divisions with separate collections for model organisms include:

- Human genes data
- Other Primates genes data
- Mus musculus genes data
- Other Rodenta genes data
- Other Mammalia genes data
- Danio rerio genes data
- Fugu rubripes genes data
- Other Vertebrata genes data
- Drosophila melanogaster genes data
- Caenorhabditis elegans genes data
- Other Invertebrata genes data
- Saccharomyces cerevisiae genes data
- Schizosaccharomyces pombe genes data
- Arabidopsis thaliana genes data
- Oryza Sativa genes data
- Zea Mays genes data
- Other eukaryotes from GB
- *.pln genes data

Annotation of Drosophila Melanogaster 2.9 MB ADH region
SUPER_LINK Chromosome 22 gene predictions
Included Drosophila melanogaster ADH 2.9 MB genomic region automatic Annotation using FGENES and FGENESH: Fgenes predictions, Fgenesh predictions, CGG1

Summary prediction using both mention above and std3 - manual annotation based on experimental data (some computational) by Ashburner et al. (1999). This example shows problems with genomic annotation: 90% of actual coding sequences predicted accurately, but exons often combined very different from real genes.

- You can save an Infogene record using Action menu and Obtain Infogene locus option (with or without sequence)
- Realized search of context (select Search fils (among many specific lines of Infogen database) and print your word in left down corner)

For example you can find all genes which have start of transcription annotated in GeneBank: Select Context in Option menu, select onlt TSP field in SearchFilds, put * in search window and Enter.

To see all information about a gene in the locus:
- Put mouse pointer to gene block in upper window and push and keep right mouse button (shift key + push and click right mouse button will permanently show this information) LocusInfo button will show a head of locus which shows how many GenBank entries are used for gene description.

Geneid
http://www1.imim.es/software/geneid

Geneid is a program to predict genes in anonymous genomic sequences from eukariotic organisms. Main features:
- Very efficient in terms of speed and memory usage. In the practice, geneid can analyze chromosome size sequences in minutes.
- Rudimentary support to integrate predictions from multiple sources, and to reanotate genomic sequences, via external gff files and the redefinition of the "gene model".
- Customizable levels of output, including exhaustive listing of potential signals and exons.
- source code, compiled binaries for some architectures and documentation available under the GNU GPL license.

Download geneid directly through anonymous ftp to monstre.imim.es in /pub/software/geneid

Enrique Blanco Garcia
Genome Informatics Group
FIB-upc ** IMIM-upf
Extended Human Variation Panels
(http://locus.umdnj.edu/nigms)

The National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository has assembled four extended human variation panels for distribution as individual cell cultures and/or DNA panels. Two of these panels include Caucasians available either as 50 individuals (25 males and 25 females) or 100 individuals (51 males and 49 females). Two other panels are composed of African Americans available either as 50 individuals (14 males and 36 females) or 100 individuals (17 males and 83 females). Additional smaller human variation panels are also available. Information about these samples is available via the world wide web (http://locus.umdnj.edu/nigms) or by contact with the Repository.

NIGMS Human Genetic Cell Repository
Coriell Cell Repositories
Coriell Institute for Medical Research
401 Haddon Avenue
Camden, New Jersey 08103
Telephone:800-752-3805 in the United States
609-757-4848 from other countries
Fax: 609-757-9737
e-mail: ccr@arginine.umdnj.edu
Jeanne C. Beck, Ph.D.
Deputy Director
Coriell Cell Repositories
401 Haddon Avenue
Camden, New Jersey 08103
Voice:856-757-4847
Fax:856-757-9737
e-mail:jbeck@umdnj.edu

National Cancer Institute Clinical Trials Gateway Web
http://cancertrials.nci.nih.gov/system/

Every year, 20,000 patients participate in NCI-sponsored clinical trials, the best method for advancing cancer care. But it still takes too long to answer important treatment questions.

That's why a fundamental change is under way in how the National Cancer Institute (NCI) develops, reviews, conducts, and supports clinical trials. The revitalized system is more flexible and more inclusive, inviting input from basic and clinical researchers, community and research oncologists, patients and families, and every group with a commitment to improving cancer care. Several pilot projects are happening, and several more are approaching reality.

The new initiatives are divided into five categories: Broadening Access. Opening clinical trials to more physicians and patients will mean quicker answers to vital cancer research questions.

Generating New Ideas. Canvassing a broad range of basic and applied scientists from both academia and industry will cast a wide net for the most promising new therapies.

Educating and Communicating. Reaching out to physicians and patients will bring more people into the clinical trials system and reinforce the message that clinical trials are critical.

Streamlining Procedures. Reducing paperwork and consolidating procedures will ease clinical trials participation for physicians while maintaining safety and quality.

Automating Data Systems. Virtually every component of the new system will be online.

CancerTrials (http://cancertrials.nci.nih.gov) is NCI's comprehensive clinical trials site, providing access to NCI's clinical trials database, news about cancer research, and resources for patients and health professionals about participating in clinical trials.

Primate Materials
(http://locus.umdnj.edu/nia)

The National Institute on Aging (NIA) Aging Cell Repository has assembled panels of primate materials for distribution. These panels contain samples from the...
following nonhuman primates: ring-tailed lemur, black-handed spider monkey, woolly monkey, red-bellied tamarin, pig-tailed macaque, rhesus macaque, orangutan, gorilla, chimpanzee, and bonobo. These samples are available either as fibroblast cultures or DNA. Additional information can be obtained at http://locus.umdnj.edu/nia or by contact with the Repository.

The NIA Aging Cell Repository
Coriell Cell Repositories
401 Haddon Avenue
Camden, NJ 08103

Telephone: 800-752-3805 within the United States
856-757-4848 from other countries
Fax: 856-757-9737
e-mail: ccr@arginine.umdnj.edu

Jeanne C. Beck, Ph.D.
Deputy Director
Coriell Cell Repositories
401 Haddon Avenue
Camden, New Jersey 08103
Voice: 856-757-4847
Fax: 856-757-9737
e-mail: jbeck@umdnj.edu

parallel-design clinical trial to determine whether ingested (oral) human recombinant IFN-α will prolong the ‘honeymoon’ period. We have demonstrated that ingested IFN-α prevents type 1 diabetes in the NOD mouse. Ingested IFN-α also prolongs the ‘honeymoon’ period in newly diagnosed type 1 diabetics in phase I open label clinical trial recently completed here at UT-Houston. The natural history of type 1 diabetes is unique for a phase frequently referred as the “honeymoon”, a period in which the insulin need becomes minimal and glycemic control improves. The β cell partially recovers. However, as with all honeymoons, they end and the patient becomes completely insulin-deficient. The general consensus of the international diabetes community is to test potential preventive therapies for type 1 diabetes in newly diagnosed patients. Prolongation of the honeymoon as the reversal of the disease is considered a positive result.

Entry criteria include male or female type 1 diabetes patients requiring insulin within one month of diagnosis between the ages of 3-25 without concurrent diseases. Eighty eligible patients will be randomized into one of two treatment arms - the active treatment arm will ingest 30,000 units IFN-α daily and the non-active treatment arm will ingest placebo (saline) for one year.

Prior to enrollment into the study (within 1 month of diagnosis), patients will be evaluated in the UT University Clinical Research Center at Hermann Hospital with a complete medical exam and routine blood tests. Patients will be seen monthly for the first three months, and every three months thereafter. Primary outcome measures will be a 30% increase in C-peptide levels released after Sustacal stimulation at 3, 6, 9, and 12 months after entry. If successful, this will lead to a larger and longer phase III trial of prevention of type 1 diabetes in high risk patients.

We appreciate your help in referring patients to our Diabetes Research Group. Your efforts allow patients the opportunity to be involved in cutting edge clinical trials. There is no charge to your patients. Patients will continue to be followed by their private endocrinologist for optimization of glycemic control during the course of the study. This trial will require trips to Houston at entry and at months 1, 2, 3, 6, 9, and 12 for testing.
If you have or know of patients that might wish to participate in this clinical trial outlined above, please call any of the numbers below.

Staley A. Brod, MD Principal Investigator - 713 500-7046 or 713 500-7050

THE UNIVERSITY OF TEXAS DIABETES RESEARCH GROUP NEWSLETTER presents new information on studies of oral (ingested) type I interferon. The Endocrinology Divisions in both Internal Medicine and Pediatrics are now recruiting newly diagnosed type 1 diabetes patients in a phase II randomized, double-blind, clinical trial to determine whether ingested (oral) human recombinant IFN-α will prolong the ‘honeymoon’ period. We have demonstrated that ingested IFN-α prevents type 1 diabetes in the NOD mouse. Ingested IFN-α also prolongs the ‘honeymoon’ period in newly diagnosed type 1 diabetics in phase I open label clinical trial recently completed here at UT-Houston. The natural history of type 1 diabetes is unique for a phase frequently referred as the “honeymoon”, a period in which the insulin need becomes minimal and glycemic control improves. The β cell partially recovers. However, as with all honeymoons, they end and the patient becomes completely insulin-deficient. The general consensus of the international diabetes community is to test potential preventive therapies for type 1 diabetes in newly diagnosed patients. Prolongation of the honeymoon as the reversal of the disease is considered a positive result.

Entry criteria include male or female type 1 diabetes patients requiring insulin within one month of diagnosis between the ages of 3-25 without concurrent diseases. Eighty eligible patients will be randomized into one of two treatment arms - the active treatment arm will ingest 30,000 units IFN-α daily and the non-active treatment arm will ingest placebo (saline) for one year.

Prior to enrollment into the study (within 1 month of diagnosis), patients will be evaluated in the UT University Clinical Research Center at Hermann Hospital with a complete medical exam and routine blood tests. Patients will be seen monthly for the first three months, and every three months thereafter. Primary outcome measures will be a 30% increase in C-peptide levels released after Sustacal stimulation at 3, 6, 9, and 12 months after entry. If successful, this will lead to a larger and longer phase III trial of prevention of type 1 diabetes in high risk patients.

We appreciate your help in referring patients to our Diabetes Research Group. Your efforts allow patients the opportunity to be involved in cutting edge clinical trials. There is no charge to your patients. Patients will continue to be followed by their private endocrinologist for optimization of glycemic control during the course of the study. This trial will require trips to Houston at entry and at months 1, 2, 3, 6, 9, and 12 for testing. If you have or know of patients that might wish to participate in this clinical trial outlined above, please call any of the numbers below.

Staley A. Brod, MD Principal Investigator - 713 500-7046 or 713 500-7050
RULES OF THE LAB

From the Science Jokes website.
http://www.xs4all.nl/~jcdverha/scijokes/
The science jokes are collected by Joachim Verhagen (sciencejokes@xs4all.nl)

1. When you don't know what you're doing, do it neatly.
2. Experiments must be reproduceable, they should fail the same way each time.
3. First draw your curves, then plot your data.
4. Experience is directly proportional to equipment ruined.
5. A record of data is essential, it shows you were working.
6. To study a subject best, understand it thoroughly before you start.
7. To do a lab really well, have your report done well in advance.
8. If you can't get the answer in the usual manner, start at the answer and derive the question.
9. If that doesn't work, start at both ends and try to find a common middle.
10. In case of doubt, make it sound convincing.
11. Do not believe in miracles--rely on them.
12. Team work is essential. It allows you to blame someone else.
13. All unmarked beakers contain fast-acting, extremely toxic poisons.
14. Any delicate and expensive piece of glassware will break before any use can be made of it. (Law of Spontaneous Fission)

Four stages of acceptance:
From: offordj@aa.wl.com (Jim Offord)
i) this is worthless nonsense;
ii) this is an interesting, but perverse, point of view;
iii) this is true, but quite unimportant;
iv) I always said so.

Probably an adaption of the following:
Every great scientific truth goes through three stages. First, people say it conflicts with the Bible.
Next they say it had been discovered before.
Lastly they say they always believed it.
-- Louis Agassiz (Swiss naturalist, 1807-1873)

ADDITIONAL ASSOCIATE EDITORS NEEDED!!
The ISICR newsletter needs additional associate editors to help with regular columns, special features, etc. We welcome volunteers from outside the US to contribute information relevant to interferon and cytokine research in their home countries. Think of the status in being an ISICR newsletter editor! Few people can make this claim to fame! Contact Howard Young (you know, the bald guy with glasses) to join this soon to be award winning* team!!
*as soon as someone gives us an award

Future ISICR Meetings

Oct. 7-12
2001
Cleveland, OH

2002
Joint Meeting with ICS
Torino, Italy